Competitor Analysis: Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists
Product description
The present Competitive Intelligence Report about Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is thought to play a major pathological role in RA. With the recent approval of tocilizumab, a humanized anti-IL-6 receptor antibody originating from Chugai and under development at Roche in Western countries, this target has become clinically validated and now can show its commercial potential in competition with TNF blockers.
The report includes a compilation of currently active projects in research and development of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) antagonists. In addition, the report lists company-specific R&D pipelines of IL-6/R antagonists. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
The present Competitive Intelligence Report about Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists for treatment of rheumatoid arthritis and multiple myeloma provides a competitor evaluation in the field of R&D projects with Interleukin-6 (IL-6) Inhibitors and IL-6 Receptor (IL-6R) Antagonists as of October 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Although the causes of rheumatoid arthritis are not fully understood, constitutive overproduction of interleukin-6 (IL-6), a multifunctional cytokine that regulates immune response, inflammatory reaction and bone metabolism, is thought to play a major pathological role in RA. With the recent approval of tocilizumab, a humanized anti-IL-6 receptor antibody originating from Chugai and under development at Roche in Western countries, this target has become clinically validated and now can show its commercial potential in competition with TNF blockers.
The report includes a compilation of currently active projects in research and development of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) antagonists. In addition, the report lists company-specific R&D pipelines of IL-6/R antagonists. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category/Therapeutic Area,
- Indication,
- R&D Stage and additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Index
- IL-6 Inhibitors
- IL-6R Antagonists
- About La Merie
